Santaris Pharma said this week that partner Enzon has returned the rights to all of the data and intellectual property related to the locked nucleic acid drugs the companies were developing under a long-term partnership in cancer.
Santaris said it will also receive an undisclosed amount of money as part of the arrangement, and did not provide reasons behind Enzon's decision. None of the products the companies were working on were microRNA-related.